Backus Lisa I, Belperio Pamela S, Shahoumian Troy A, Loomis Timothy P, Mole Larry A
Department of Veterans Affairs, Population Health Services, Palo Alto Health Care System, Palo Alto, CA, USA.
Antivir Ther. 2017;22(6):481-493. doi: 10.3851/IMP3117. Epub 2016 Dec 9.
Predictors of sustained virological response (SVR) to all-oral HCV regimens can inform nuanced treatment decisions. We evaluated effectiveness and identified predictors of SVR for ledipasvir/sofosbuvir ± ribavirin (LDV/SOF ±RBV) and ombitasvir/paritaprevir/ritonavir + dasabuvir (OPrD) ±RBV in patients treated in routine practice.
Observational, intent-to-treat cohort of 21,142 genotype-1 patients initiating 8 or 12 weeks of LDV/SOF ±RBV or 12 weeks of OPrD ±RBV at any Veterans Affairs facility. Multivariate logistic regression models were constructed to model SVR and identify predictors.
SVR was 91.2% (9,781/10,720) for LDV/SOF, 89.6% (3,266/3,646) for LDV/SOF+RBV, 91.7% (1,197/1,306) for OPrD and 87.8% (3,365/3,832) for OPrD+RBV. For LDV/SOF ±RBV, reduced odds of SVR occurred in African-Americans (0.80, 95% CI 0.70, 0.92, P<0.001), body mass index (BMI)<25 (0.77, 95% CI 0.66, 0.90, P<0.001), BMI≥30 (0.77, 95% CI 0.67, 0.89, P<0.001), proton pump inhibitors (PPIs; 0.81, 95% CI 0.71, 0.92, P<0.001), decompensated liver disease (0.58, 95% CI 0.45, 0.74, P<0.001) and FIB4>3.25 (0.60, 95% CI 0.53, 0.69, P<0.001). For OPrD ±RBV, FIB-4>3.25 negatively predicted SVR (0.72, 95% CI 0.59, 0.88, P<0.001). Detectable 4-week on-treatment HCV RNA≥15 IU/ml reduced SVR odds for both regimens (LDV/SOF ±RBV OR 0.49, 95% CI 0.41, 0.58, P<0.001; OPrD ±RBV OR 0.38, 95% CI 0.29, 0.50, P<0.001). Receipt of OPrD+RBV compared to LDV/SOF reduced odds of SVR (OR 0.70, 95% CI 0.62, 0.80, P<0.001). Mental health diagnosis did not impact likelihood of SVR.
The diversity and size of this cohort allowed for extensive examination of regimen-specific predictors of SVR. FIB-4>3.25 and detectable 4-week on-treatment HCV RNA had the greatest negative impact. African-American race, low or high BMI, and PPIs negatively impacted odds of SVR for LDV/SOF ±RBV. Mental health diagnoses did not.
全口服丙肝治疗方案持续病毒学应答(SVR)的预测因素可为细致的治疗决策提供依据。我们评估了在常规治疗中接受来迪派韦/索磷布韦±利巴韦林(LDV/SOF±RBV)和奥比他韦/帕利哌韦/利托那韦+达沙布韦(OPrD)±RBV治疗的患者的治疗效果,并确定了SVR的预测因素。
在任何退伍军人事务机构对21142例基因型1患者进行观察性、意向性治疗队列研究,这些患者开始接受8或12周的LDV/SOF±RBV治疗或12周的OPrD±RBV治疗。构建多变量逻辑回归模型以模拟SVR并确定预测因素。
LDV/SOF的SVR为91.2%(9781/10720),LDV/SOF+RBV为89.6%(3266/3646),OPrD为91.7%(1197/1306),OPrD+RBV为87.8%(3365/3832)。对于LDV/SOF±RBV,非裔美国人(0.80,95%CI 0.70,0.92,P<0.001)、体重指数(BMI)<25(0.77,95%CI 0.66,0.90,P<0.001)、BMI≥30(0.77,95%CI 0.67,0.89,P<0.001)、质子泵抑制剂(PPI;0.81,95%CI 0.71,0.92,P<0.001)、失代偿性肝病(0.58,95%CI 0.45,0.74,P<0.001)和FIB4>3.25(0.60,95%CI 0.53,0.69,P<><>。对于OPrD±RBV,FIB-4>3.25对SVR有负向预测作用(0.72,95%CI 0.59,0.88,P<0.001)。治疗4周时可检测到的HCV RNA≥15 IU/ml降低了两种治疗方案的SVR几率(LDV/SOF±RBV的OR为0.49,95%CI 0.41,0.58,P<0.001;OPrD±RBV的OR为0.38,95%CI 0.29,0.50,P<0.001)。与LDV/SOF相比,接受OPrD+RBV治疗降低了SVR几率(OR 0.70,95%CI 0.62,0.80,P<0.001)。心理健康诊断不影响SVR的可能性。
该队列的多样性和规模允许对SVR的特定治疗方案预测因素进行广泛研究。FIB-4>3.25和治疗4周时可检测到的HCV RNA产生的负面影响最大。非裔美国人种族、低BMI或高BMI以及PPI对LDV/SOF±RBV的SVR几率有负面影响。心理健康诊断则没有。